Newsletter · · Ashutosh Agarwal

Biotech's M&A Boom Enters Its Later Innings - Biotech M&A and Drug Pricing - Week of September 4, 2026

For the week of September 4, 2026, biopharma podcasts argued the M and A supercycle is real but maturing: roughly 400 billion dollars of revenue is rolling off patent against 180 billion of deployable cash, yet RBC says the obvious buyers have already shopped and the discounts are gone. Plus the most favored nation pricing program expanding to 89 percent of the branded market and Eli Lilly's thirteenth takeout of the year.

Biotech M&A and Drug Pricing

Week of September 4, 2026: Biotech's M&A Boom Enters Its Later Innings

The best minds in biopharma spent this week arguing about the same thing from two directions: the buying spree that has powered biotech's best run in years is real and structurally unstoppable, and it is also, in the words of one of the sharpest sell-side teams around, entering its "later innings." Both things can be true, and this week they were.

Underneath that debate, the actual news kept coming. The government's drug-pricing push quietly grew large enough to cover nearly nine in ten branded medicines. Eli Lilly did its thirteenth acquisition of the year. And a couple of safety scares were a useful reminder that the shiny new science everyone is bidding on is still, well, experimental.

TL;DR

  • The M&A machine is powerful but maturing. Big drugmakers face an estimated $400 billion of revenue at risk from expiring patents over the next decade and are sitting on roughly $180 billion of spare cash to plug the hole, but the most obvious buyers have now shopped, valuations have jumped, and the pace is set to cool. Depth over breadth from here.
  • Washington's price crackdown got a lot bigger. The "most favored nation" pricing program, the idea that Americans shouldn't pay more than other rich countries, expanded from 17 big drugmakers to nine mid-sized ones, and now covers about 89% of the branded drug market.
  • Eli Lilly keeps buying, small and often. Its CEO says Lilly has done over $25 billion in announced deals this year and looks at roughly ten acquisitions a week, but its biggest deal ever is still under $8 billion. This is a strategy of many small bets, not one big swing.

What's new

1) The single most useful framing of the week: big pharma has to keep buying, but the easy part is over.

This came from RBC Capital Markets' healthcare research team on their own podcast, Pathfinders in Biopharma ("What's driving biotech's latest rally?"). This is sell-side opinion, analysts talking their book of ideas rather than company insiders, but the numbers are the clearest scorecard anyone put on the table this week.

Brian Abrams, RBC's head of global healthcare research, laid out the "why they must buy" case in one breath: there is roughly $400 billion in large biopharma revenue at risk from loss of exclusivity over the next decade, "loss of exclusivity" being the moment a drug's patent expires and cheap copies flood in, while big-pharma balance sheets hold over $180 billion in aggregate free cash flow available to be deployed. His point: the holes these companies are staring at are bigger than anything their own labs can fill, so they have to go shopping. As he put it, when you look at the sales the already-announced deals will generate, "they don't come anywhere close to filling the revenue holes that these companies are staring down. So the math still argues for more activity."

He also knocked down the two risks a bear would raise. On antitrust: "The FTC has remained permissive, and that's helped to facilitate deal flow." On timing: M&A historically "picks up around the midterm elections," which could add a catalyst later this year.

But here is the part that makes it this week's freshest idea. RBC thinks we are "in the later innings of this particular M&A cycle, even if the game isn't over." The reasoning is refreshingly concrete:

  • The natural buyers have largely gone shopping already. Abrams named Vertex, Gilead, AbbVie, Biogen, and Neurocrine as companies that have "either made significant deals recently or signaled more limited appetite for additional large-scale transactions." That "meaningfully narrows the pool of active buyers."
  • The target list is thinner too. Deals this cycle favored drugs already on the market or in late-stage testing, so you're paying for near-term revenue, and "the pipeline of similar quality public targets is a bit thinner than it was."
  • And the bargains are gone. With biotech stocks having jumped, "it's harder to offer a compelling premium on a name that's already pricing in a takeout."

RBC's colleague Lisa Walter added the investor mood, from a survey of 60-plus specialist and generalist funds taken right at the peak of the rally in July. M&A is still the number one thing investors are excited about, cited by 70%. But 55% now think biotech is fairly valued and 23% think it's overvalued, up from just 6% six months earlier, while the share calling it undervalued collapsed from 52% to 22%. Translation: everyone still likes the story, but almost no one thinks it's cheap anymore.

2) Washington's price crackdown just got much bigger, the most important hard news of the week.

Two podcasts caught the same development from different angles. The short version, from journalists at BioSpace ("Novartis' and BMS' paused CAR T trials, RevMed's pancreatic cancer approval, more MFN deals"): the White House's "most favored nation" (MFN) drug-pricing program, the rule that the US shouldn't pay more for a medicine than other wealthy countries do, has expanded again. After signing up 17 large drugmakers last year, the administration just struck deals with nine mid-sized companies, including Astellas, UCB and Teva, who "collectively committed nearly $20 billion in manufacturing investments in the U.S." The upshot: MFN deals now cover about 89% of the branded drug market. Signing shields a company from tariffs, but it can also take them out of the running for a coming Medicaid pricing program aimed at the same goal.

The regulatory reporters at Citeline's "Drug Fix" ("MFN Finds Mid-Size Companies And More Vaccine Policy Moves") added the texture that matters for investors. Two things to watch:

  • The terms don't fit small companies. The Pink Sheet editors pointed out that mid-size and small biotechs "can't behave the same way" as the giants: many don't control their overseas rights, can't fund a direct-to-patient sales website, and outsource their manufacturing, so a promise to expand a US plant isn't theirs to make. Some drugmakers have flatly warned that if they can't hold prices up abroad, "we will stop launching new drugs" in those markets.
  • It may all be temporary. The editors noted a widely held expectation that these agreements are "not, in fact, going to extend beyond the president's term" in 2028, and that a coming Medicare pricing demonstration, if it goes live, will almost certainly draw lawsuits. So this is a real overhang, but a fluid one.

Why it matters for the M&A story: RBC said drug-pricing fear has "receded from the forefront," and the deal machine has been humming despite MFN. This week's expansion is a reminder that the policy backdrop is quietly getting heavier, not lighter, and RBC itself warned the midterms "do historically have a way of bringing the policy risk back into focus."

3) The Eli Lilly buying machine, heard straight from the CEO, and from the people watching him.

This was the rare case where we got both the operator and the commentators on the same deal in the same week. On Monday, Lilly agreed to buy Merida Biosciences for up to about $2.88 billion in cash, a four-year-old, privately held Cambridge, Massachusetts immunology company.

The operator's voice: Lilly CEO Dave Ricks, in a CNBC interview on Squawk on the Street ("Exclusive Interviews with the CEOs of Goldman Sachs and Eli Lilly"), speaking from the G20. His framing of Lilly's approach: "Year-to-date we've done more deals this year than we did all of last year... we've probably done over $25 billion in announced deals." On Merida specifically: "It's an early phase deal. That's sort of our sweet spot," aimed at a "novel approach to knock out those pathogenic autoimmune antibodies." And on why he'd rather buy than sit on cash: "The company is doing well. We're generating a lot of cash flow. We'd rather invest that in our future."

The commentators' voice: Bloomberg Intelligence's Michelle Cortez, a journalist, on the Bloomberg Intelligence podcast, gave the pattern behind the headline. Lilly, she said, has "told us that they look at 10 different acquisitions every single week... they're pulling the trigger a lot, but they're pulling it at a very low rate." The strategy in one line: "They're doing massive numbers in terms of deals, not massive size of the deals themselves." Crucially, "the biggest deal that Lilly has ever done is sub-$8 billion", tiny next to a company its size. Cortez tied it back to history: Lilly got burned when Prozac lost patent protection and "had to scramble," so it is buying early-stage science now to have "future income streams" when its blockbuster obesity drugs eventually face copies, pressure she doesn't see biting "for another five to eight years."

The trade press filled in the ledger. BioCentury This Week ("MFN deals, Lilly takeout, FDA pick Overton") noted Merida is Lilly's 13th takeout of the year, and that "on acquisitions alone, they've spent at least $31.5 billion in total... at least $22.6 billion has been in upfront payments." It's their fourth immunology deal of the year, after in-vivo CAR-T buys Colonia (up to $6.8 billion) and Orna (up to $2.4 billion), plus Ventix (about $1.2 billion) in January. The takeaway a PM should file away: this is a company treating deal-making like a venture portfolio, spreading lots of small bets, expecting most to fizzle, and letting a few pay for all of it.

4) The rally's plumbing: deals are outrunning fundraising, and that's the tell.

The most quantitatively useful discussion of the sector's health came from the specialist investors on Biotech Hangout ("Episode 194"). These are buy-side voices, people who own the stocks, so treat it as informed opinion rather than gospel.

Host Daphne Zohar walked through why this rally looks different from the last biotech mania in 2021. Back then, small- and mid-cap ("SMID") biotech takeovers ran about $67 billion while companies raised about $66 billion in stock, so buying and fundraising were balanced. This past year, SMID biotech M&A has run around $143 billion, more than double the 2020–21 pace, against only about $59 billion of stock issuance. In plain terms: big companies are buying biotechs far faster than those biotechs are printing new shares, which shrinks the supply of stock and helps explain why the sector's benchmark, the XBI index, is up roughly 80% over the past year versus about 20% for the S&P 500. She also flagged that IPOs are back but pickier, 20 so far this year versus 9 in all of 2025, with "no preclinical IPO this cycle versus 19 in the year before the last peak." The market is rewarding proof, not promises.

One subtle point worth keeping: Zohar noted that even as more bidders chase each deal, premiums have actually been compressing, because the takeout is already baked into the stock price before the offer arrives. That's the same wall RBC described from the other side.

5) A reality check: the science being bought is still risky.

Two safety scares landed this week, via BioSpace. Novartis paused several trials of a CAR-T therapy for autoimmune diseases after three patient deaths from a known but rare immune complication; Bristol-Myers Squibb paused some of its own autoimmune CAR-T studies over "transient and reversible inflammatory events." (CAR-T means engineering a patient's own immune cells to attack disease: powerful, but it can overshoot.) An analyst at William Blair, cited on the show, noted this "highlights the risk of CAR-T in autoimmune and could potentially reduce competition in a crowded space." Given how much M&A this cycle has validated exactly this kind of cutting-edge biology, it's a healthy reminder that "differentiated science" and "de-risked" are not the same thing.

And on the flip side of the takeout math: BioSpace flagged that Revolution Medicines won an early FDA approval for its pancreatic-cancer drug and is being called a possible "next oncology titan," prompting the hosts' aside, "no wonder they wouldn't let Merck buy them," referencing a reported $33 billion approach the company walked away from. Sometimes the best target is the one that decides it doesn't need you.

The debate

This week the argument was genuinely two-sided, and unusually, both sides came mostly from the same RBC discussion, which steel-manned each in turn.

The bull case (M&A supercycle): The patent cliff is a math problem, not a mood. About $400 billion of revenue is rolling off patent over the next decade and internal pipelines can't fill it, while big pharma sits on $180+ billion of deployable cash. Regulators are permissive ("the FTC has remained permissive"), Lilly alone is doing a deal a week, and midterm-year seasonality could add fuel. Investors agree the direction of travel: 70% call M&A the sector's biggest tailwind.

The bear and caution case (late-cycle selectivity): The obvious buyers, Vertex, Gilead, AbbVie, Biogen and Neurocrine, have largely already bought or signaled they're done, "narrowing the pool of active buyers." The best late-stage targets have been picked over. Valuations have re-rated so hard that offering a premium is difficult and, as Biotech Hangout noted, premiums are actually shrinking. And 23% of investors now call the sector overvalued, up from 6%. Add a policy backdrop that just quietly expanded (MFN to 89% of branded drugs) and could flare at the midterms, plus this week's CAR-T safety pauses, and the risk-reward on any single name gets harder to underwrite.

Notably, the classic bear leg, antitrust risk, went essentially unvoiced this week, and where it came up it was dismissed: RBC called the FTC permissive, and Bloomberg said Lilly's early-stage buys "aren't really getting the attention of regulators." So the real fight this week wasn't bull versus bear on whether deals happen; it was supercycle versus maturity on how many are left and at what price.

The names in play

  • Eli Lilly (LLY) is the week's most-discussed buyer, and the clearest strategy: many small, early-stage bets (13 deals year to date, $31.5B spent, biggest-ever still under $8B), heavy in immunology, funded by obesity-drug cash flow, with the CEO on the record that this is deliberate.
  • Merida Biosciences (private) is Lilly's latest, up to about $2.88B, an immunology play targeting disease-causing antibodies, and the template for the kind of early-stage asset getting bought.
  • Vertex, Gilead, AbbVie, Biogen, Neurocrine were named by RBC as buyers who have stepped back. If you're underwriting further mega-deals, this is the list of firepower that may be sidelined near-term.
  • Revolution Medicines (RVMD) is a would-be target that walked, reportedly turning down a roughly $33B Merck approach after an early cancer-drug approval. A reminder that the strongest SMID names now have the leverage to stay independent.

Read-throughs

  • XBI and SMID biotech sentiment: constructive but no longer cheap. The clearest read of the week. Investors are staying long but not adding: 64% plan to hold exposure (up from 56%), only 30% plan to add (down from 40%). RBC's advice is to favor larger-cap names with real cash flow as the "core" and to hunt selectively among SMID names that lagged or pulled back. As one analyst put it, the second half will "reward selectivity more than it rewards breadth."
  • How to pick biotechs when nothing looks cheap. A useful sidebar from value investors Dan Rasmussen and Kai Wu on Excess Returns: because biotechs have "no assets, no revenue," they screen on three proxies for hidden value, namely market value relative to cumulative R&D spend, how much of the stock is owned by specialist biotech investors versus tourists, and low short interest. Names that score well on all three, they argue, "massively outperform." A sensible lens for a richly-valued tape.
  • China as a deal source. RBC flagged that more business development is turning toward China, where competitive drug molecules can be licensed "for a lower cost," a structural shift that could keep deal flow alive even as US targets get expensive, and one that even mid-size biotechs can now play.
  • Franchise-level cliffs stayed at the aggregate level. The cliff was discussed as a $400B system-wide number rather than franchise by franchise, so there was no fresh, specific commentary on Merck's Keytruda switch to an under-the-skin shot, Bristol's Eliquis, J&J's Stelara erosion, or AbbVie's post-Humira recovery. Worth noting before you underwrite any single franchise off this week's tape.

The bottom line

The conversation this week moved up a level of abstraction: away from any single franchise's cliff and toward the whole system of the M&A cycle, how much revenue is at risk ($400B), how much dry powder exists ($180B), who's still buying, and whether the boom is early or late.

The genuinely new development is the maturity call. Prior weeks leaned pure supercycle; this week the most credible voice on the tape argued we're in the "later innings," with the obvious buyers tapped out and valuations too high to pay up. Paired with the concrete policy step, MFN quietly expanding to cover 89% of branded drugs, the tone shifted from "buy the boom" to "the boom is real, but be picky, because both the targets and the discounts are getting scarce."